| 摘要 |
A compound of formula (I), its use for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma, wherein: (a) R1 is CO2H, C(O)NHOH, CO2R7 CH2OH, S(O)2R7, C(O)NHR7, C(O)NHS(O)2R7, or tetrazole; characterized in that R7 is alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; (b) W is O, NH, S, S(O), S(O)2, or (CH2)m; wherein, m is 0 to 3; (c) R2 is H and R3 is H or lower alkyl, or R2 and R3 together form a covalent bond; (d) R4 is H, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; (e) each R5 is independently selected from the group consisting of H, CH3, and C2H5; (f) X is NHR8 or OR8, characterized in that each R8 is independently selected from the group consisting of H, acyl, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, and monocyclic heteroaromatic ring; (g) each R6 is independently selected from the group consisting of H, CH3, C2H5, OR8, and NHR8; (h) Y is O, NHR8, S, S(O), or S(O)2; (i) Z is H, methyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, monocyclic heteroaromatic ring, bicyclic carbocyclic aliphatic ring, bicyclic heterocyclic aliphatic ring, bicyclic aromatic ring, or bicyclic heteroaromatic ring, provided that when Y is S, S(O), or S(O)2 and Z is H, q is at least 1; (j) a and b are independently selected from the group consisting of single bond, cis double bond, and trans double bond; (k) p is an integer from 1 to 5, q is an integer from 0 to 5, and p + q is 1 to 5; and any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
|
